[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"femoral-head-necrosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:femoral-head-necrosis":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100611443","phase-4-outcomes-from-hyperbaric-oxygen-hbo2-treatment-for-emerging-indications-100611443",false,"NCT07240649","Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications","Emerging Indications for Hyperbaric Oxygen Treatment","Inclusion Criteria:\n\n* Patients referred for HBOT with an emerging indication\n\nExclusion Criteria:\n\n* Contraindication to hyperbaric oxygen treatment (untreated seizures, pneumothorax, significant pulmonary airspace pathology that might lead to pulmonary barotrauma, unmanageable confinement anxiety, chronic obstructive pulmonary disease with CO2 retention)\n* Pregnant persons","ALL",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The research team hypothesizes that HBOT will result in improvements of the condition of the various emerging indications.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65],"Post-COVID-19 Condition","Ulcerative Colitis","Crohn Disease","Calciphylaxis","Frostbite","Acute COVID-19","Pyoderma Gangrenosum","Pterygium","Hypospadias","Head Trauma","Pneumatosis Intestinalis","Ischemic Bowel","Raynaud Syndrome","Malignant Otitis Externa","Nonarteritic Anterior Ischemic Optic Neuropathy","Central Retinal Vein Occlusion","Femoral Head Necrosis","Invasive Fungal Infection","Chronic Anal Fissure","Vasculitic Ulcer","Graft-vs-Host Disease","Decubitus Ulcer","Greater Trochanteric Pain Syndrome","Rectovaginal Fistula","Pouchitis","Tinnitus","Clostridium Enterocolitis","Branch Retinal Artery Occlusion","Axonotmesis","Multiple Sclerosis","Inclusion Body Myositis","Epidermolysis Bullosa (EB)","Osteonecrosis","Ulcer Ischemic","Avascular Necrosis of Bone","Prosthesis Related Infections","Facial Filler Injections","Cystitis Chronic","Ligament Injury","Anastomosis, Leaking","Cartilage Injury","NOT_YET_RECRUITING","2026-05-01",{"date":69,"type":70},"2026-05-05","ACTUAL",{"date":72,"type":19},"2026-08",{"date":74,"type":19},"2035-12",{"name":76,"class":77},"Jay C. Buckey Jr.","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":20,"phases":88,"briefSummary":90,"conditions":91,"keywords":98,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100588786","phase-2-the-effect-of-oxytocin-nasal-spray-on-preventing-postoperative-delirium-in-elderly-patients-undergoing-orthopedic-surgery-100588786","NCT06945926","The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery","The Effect of Oxytocin Nasal Spray on Preventing Postoperative Delirium in Elderly Patients Undergoing Orthopedic Surgery：Two-Stage Designs for Phase II Clinical Trials","Elderly patients undergoing orthopedic surgery under general anesthesia\n\nInclusion criteria:\n\n1. Age ≥ 65 years;\n2. Patients who were to undergo elective orthopedic surgery under general anesthesia with tracheal intubation;\n3. ASA class I-III;\n4. Estimated duration of surgery ≥ 1 hour; (5) The patient himself\u002Fherself or his\u002Fher legal representative;\n5. Informed consent from the patient or legal representative;\n6. Proficiency in the use of Chinese language for communication.\n\nExclusion criteria:\n\n1. Nasal cavity occupation, patients with fillers in the nose\n2. Oxytocin allergy;\n3. Patients with previous psychiatric and neurological disorders, such as depression, severe central nervous system depression, Parkinson's disease, basal ganglia disease.\n\n   Goldson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, and so on;\n4. Pregnant and lactating women\n5. Patients with severe hepatic insufficiency (Child-Pugh class C);\n6. patients with severe renal insufficiency (dialysis is required before surgery)\n7. Severe heart failure (METS\\\u003C4);\n8. Preoperative inability to communicate (coma or dementia);\n9. Severe preoperative blindness, deafness, or inability to understand Mandarin to complete preoperative delirium screening;\n10. Preoperative cognitive impairment as determined by a MoCA evaluation prior to surgery;\n11. Patients who are scheduled for 2 surgeries within 7 days of surgery;\n12. Patients with bone malignancy\n13. Currently participating in other clinical trials.","65 Years",{"count":87,"type":19},220,[89],"PHASE2","Postoperative delirium is a delirium that occurs within 7 days after surgery or before hospital discharge. It has been shown that combined POD can increase the incidence of postoperative pulmonary infections, deep vein thrombosis and decubitus ulcers, and increase the incidence of disability and mortality. The incidence of postoperative delirium in geriatric orthopedics is high.\n\nInvestigators conduct a prospective clinical study on geriatric orthopedic surgery patients to investigate the effect of oxytocin nasal spray on the prevention of postoperative delirium in geriatric orthopedic surgery. Cases were included according to the inclusion and exclusion criteria, and induction, maintenance and resuscitation were performed according to the standard protocol for general anesthesia. Before the end of surgery, the Investigators administered oxytocin nasal spray (Oxytocin) that was 3 sprays in each nostril (4 IU each) for a total of 24 IU. Beginning 1 day postoperatively, administer 24 IU of oxytocin nasal spray 2 times\u002Fday in the morning and in the evening. Until 7 days after surgery or discharge. The sample size are 77 cases in phase I and 143 cases in phase 2, total 220 cases.",[92,93,94,95,41,96,97],"Cervical Spinal Stenosis","Thoracic Spinal Stenosis","Lumbar Spinal Stenosis","Rotator Cuff Injury","Spinal Trauma","Knee Joint Injury",[99,100,101],"Postoperative delirium","elderly orthopedics","oxytocin nasal spray","2025-05-23",{"date":104,"type":70},"2025-05-25",{"date":106,"type":19},"2025-06-01",{"date":108,"type":19},"2026-06-30",{"name":110,"class":77},"Zhejiang University",1]